- Home
- EQS vs SLGL Comparison
EQS vs SLGL Comparison
Compare EQS & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQS
- SLGL
- Stock Information
- Founded
- EQS 1991
- SLGL 1997
- Country
- EQS United States
- SLGL Israel
- Employees
- EQS N/A
- SLGL N/A
- Industry
- EQS Finance Companies
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- EQS Finance
- SLGL Health Care
- Exchange
- EQS Nasdaq
- SLGL Nasdaq
- Market Cap
- EQS 20.1M
- SLGL 19.3M
- IPO Year
- EQS N/A
- SLGL 2018
- Fundamental
- Price
- EQS $1.88
- SLGL $15.20
- Analyst Decision
- EQS
- SLGL Buy
- Analyst Count
- EQS 0
- SLGL 1
- Target Price
- EQS N/A
- SLGL $40.00
- AVG Volume (30 Days)
- EQS 52.3K
- SLGL 19.4K
- Earning Date
- EQS 01-01-0001
- SLGL 08-19-2025
- Dividend Yield
- EQS N/A
- SLGL N/A
- EPS Growth
- EQS N/A
- SLGL N/A
- EPS
- EQS N/A
- SLGL N/A
- Revenue
- EQS $1,329,000.00
- SLGL $12,103,000.00
- Revenue This Year
- EQS N/A
- SLGL N/A
- Revenue Next Year
- EQS N/A
- SLGL $31.17
- P/E Ratio
- EQS N/A
- SLGL N/A
- Revenue Growth
- EQS 152.66
- SLGL 603.66
- 52 Week Low
- EQS $0.74
- SLGL $3.83
- 52 Week High
- EQS $2.11
- SLGL $16.89
- Technical
- Relative Strength Index (RSI)
- EQS 87.93
- SLGL 76.28
- Support Level
- EQS $1.35
- SLGL $14.86
- Resistance Level
- EQS $1.83
- SLGL $16.89
- Average True Range (ATR)
- EQS 0.12
- SLGL 1.33
- MACD
- EQS 0.02
- SLGL 0.17
- Stochastic Oscillator
- EQS 57.89
- SLGL 74.10
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.